Stereotaxis, Inc. (STXS)
Stock Price Chart
Key Info
| Market Cap | 263.00M |
| Revenue (ttm) | 26.20M |
| Net Income (ttm) | -4.93M |
| Shares Out | 73.26M |
| EPS (ttm) | -0.09 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Oct 16, 2020 |
| Last Price | $3.59 |
| Previous Close | $3.65 |
| Change ($) | -0.06 |
| Change (%) | -1.64% |
| Day's Open | 3.63 |
| Day's Range | 3.52 - 3.70 |
| Day's Volume | 138,926 |
| 52-Week Range | 1.70 - 5.82 |
More Stats
| Market Cap | 263.00M |
| Enterprise Value | 224.48M |
| Earnings Date (est) | Nov 4, 2020 |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 73.26M |
| Float | 62.01M |
| EPS (basic) | -0.09 |
| EPS (diluted) | -0.09 |
| FCF / Share | -0.08 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
| Payout Ratio | n/a |
| Shares Short | 1.90M |
| Short Ratio | 7.79 |
| Short % of Float | 3.07% |
| Beta | 1.33 |
| PE Ratio | n/a |
| Forward PE | n/a |
| P/FCF Ratio | n/a |
| PS Ratio | 10.04 |
| PB Ratio | 7.50 |
| Revenue | 26.20M |
| Operating Income | -5.20M |
| Net Income | -4.93M |
| Free Cash Flow | -5.75M |
| Net Cash | 38.51M |
| Net Cash / Share | 0.53 |
| Gross Margin | 86.91% |
| Operating Margin | -19.86% |
| Profit Margin | -24.20% |
| FCF Margin | -21.94% |
| ROA | -8.30% |
| ROE | -21.44% |
| ROIC | -97.60% |
Analyst Summary
Analyst Consensus: Buy
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 28.90 | 29.35 | 31.14 | 32.16 | 37.67 | 35.01 | 38.03 | 46.56 | 41.99 | 54.05 |
| Revenue Growth | -1.51% | -5.77% | -3.17% | -14.63% | 7.61% | -7.94% | -18.32% | 10.9% | -22.32% | - |
| Gross Profit | 22.77 | 23.63 | 20.39 | 24.63 | 27.24 | 26.79 | 27.03 | 31.78 | 29.49 | 38.49 |
| Operating Income | -4.83 | -2.46 | -5.92 | -6.43 | -5.41 | -5.38 | -8.84 | -10.63 | -31.94 | -18.96 |
| Net Income | -4.59 | 0.12 | -5.89 | -5.29 | -7.35 | -5.20 | -68.76 | -9.24 | -32.03 | -19.92 |
| Shares Outstanding | 63.05 | 52.08 | 22.61 | 21.81 | 21.11 | 19.95 | 11.55 | 6.94 | 5.48 | 5.05 |
| Earnings Per Share | -0.10 | -0.03 | -0.32 | -0.54 | -0.35 | -0.26 | -5.95 | -1.33 | -5.84 | -3.94 |
| Operating Cash Flow | -4.62 | -2.55 | -4.67 | -6.56 | -2.53 | -9.09 | -6.33 | -12.12 | -31.57 | -18.91 |
| Capital Expenditures | -0.03 | -0.27 | -0.08 | -0.41 | -0.15 | -0.12 | - | -0.13 | -1.03 | -0.72 |
| Free Cash Flow | -4.65 | -2.81 | -4.76 | -6.97 | -2.68 | -9.22 | -6.33 | -12.25 | -32.60 | -19.63 |
| Cash & Equivalents | 30.18 | 10.80 | 3.69 | 8.50 | 5.59 | 7.27 | 13.78 | 7.78 | 13.95 | 35.25 |
| Total Debt | 4.34 | - | - | - | 18.08 | 18.39 | 18.53 | 29.09 | 38.46 | 28.89 |
| Net Cash / Debt | 25.84 | 10.80 | 3.69 | 8.50 | -12.49 | -11.12 | -4.76 | -21.31 | -24.51 | 6.35 |
| Assets | 43.58 | 18.51 | 10.67 | 20.97 | 18.88 | 23.88 | 31.08 | 32.17 | 39.93 | 65.76 |
| Liabilities | 15.06 | 11.24 | 31.27 | 36.50 | 36.50 | 36.43 | 42.78 | 50.96 | 58.76 | 55.29 |
| Book Value | 22.77 | 1.31 | -26.57 | -21.49 | -17.63 | -12.55 | -11.70 | -18.79 | -18.83 | 10.48 |
Company Profile
Company Details
| Full Name | Stereotaxis, Inc. |
| Country | United States |
| Employees | 118 |
| CEO | David Leo Fischel |
Stock Information
| Ticker Symbol | STXS |
| Stock Exchange | NYSE American |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Unique Identifier | NYSEAMERICAN: STXS |
| IPO Date | August 12, 2004 |
Description
Stereotaxis designs, manufactures, and markets robotic magnetic navigation (RMN) systems for use in hospital's interventional surgical suite to enhance the treatment of arrhythmias and coronary artery disease in the United States and internationally. Its RMN systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites; and Vdrive system that offers navigation and stability for the diagnostic and therapeutic devices designed to enhance interventional procedures. The company also provides Odyssey solution, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane and full-power x-ray system, including c-arm, powered table, motorized boom, and large high-definition monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company provides various disposable components V-Loop, V-Sono, and V-CAS devices; and V-CAS Deflect catheter advancement systems. It markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with Osypka AG to develop a next-generation magnetic ablation catheter using Stereotaxis' robotic technology. Stereotaxis, Inc. was founded in 1990 and is headquartered in St. Louis, Missouri.